## **Special Issue**

# Marine Natural Products with Antiprotozoal Activity

### Message from the Guest Editors

Infections caused by protozoan parasites are responsible for a large number of severe and widespread diseases which include malaria, leishmaniasis, Chagas disease or human African trypanosomiasis, among others. They mostly affect rural and poor urban areas of tropical and subtropical regions causing a considerable morbidity and mortality worldwide. Current drug treatments are ineffective due to drug resistance and toxicity in addition to their high cost and prolonged treatments. The search for new lead compounds with novel mechanisms of action for development of more effective treatments with fewer side effects represents a crucial challenge.

The marine environment is plenty of microorganisms, algae and marine invertebrates which are a rich potential source of novel molecules with high structural diversity and "drug-like" properties. As of this Special Issue of Marine Drugs, We encourage scientists working in any field involving marine natural products with antiprotozoal activities to submit recent research that may lead to significant advances.

### **Guest Editors**

Dr. Ana R. Díaz-Marrero

Instituto de Productos Naturales y Agrobiología (IPNA), Consejo Superior de Investigaciones Científicas (CSIC), Avenida Astrofísico Francisco Sánchez 3, 38206 La Laguna, Tenerife, Spain

### Dr. Jacob Lorenzo-Morales

Departamento de Obstetricia, Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad de La Laguna (ULL), Avda. Astrofísico F. Sánchez, 2, 38206 La Laguna, Tenerife, Spain

### Deadline for manuscript submissions

closed (30 December 2019)



# **Marine Drugs**

an Open Access Journal by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/23224

Marine Drugs Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 marinedrugs@mdpi.com

mdpi.com/journal/marinedrugs





an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

### **Editor-in-Chief**

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

